We analyzed the relationship of urine TFF3 levels with clinicopathological parameters and responses to chemotherapy and did not find a significant difference between urine TFF3 levels based on clinical stage, lymphatic metastasis, the patient’s gender or age, the site and degree of differentiation of the tumor or responses to chemotherapy for gastric or colorectal cancer (Tables 3 and 4). This evidence concerns the gene TFF3 and neoplasm.